StockNow
Calendar
Log in
U.S. Markets

Merck (MRK) announces that the US FDA has approved an update to the US product label for WINREVAIR for injection, 45mg, 60mg, based on the Phase 3 HYPERION trial.

StockNow breaking-news AI analysis

The US FDA approved an update to the US product label for Merck's WINREVAIR injection (45mg, 60mg) based on Phase 3 HYPERION trial data.

1 stocks
MRKMerck & Co., Inc.$149.66Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Iranian Parliament Speaker Ghalibaf says US President Trump cannot impose his power on Iran, adding that Iran will neither shut down nor surrender

Geopolitics

IRGC says if Iran’s national interests require negotiations alongside war, then it must negotiate; says it will respond to any enemy strike with multiple strikes across different arenas and in various ways, Al Jazeera reports

Geopolitics

Senior Iranian Official says that Tehran welcomes revival of diplomacy if the US takes tangible steps